Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 9 Neoplasms 3 Medulloblastoma 2 Brain Neoplasms 2 Sarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Neoplasm Recurrence, Local 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia-Lymphoma, Adult T-Cell 1 Kidney Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Gliosarcoma 1 Glioma 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1 Bone Neoplasms 1

Interventions

Cyclophosphamide 25 fludarabine 19 Dexamethasone 17 pembrolizumab 13 Rituximab 12 venetoclax 9 Lenalidomide 9 Gemcitabine 9 Etoposide 9 pomalidomide 8 Vincristine 7 glofitamab 6 fludarabine phosphate 6 carfilzomib 6 Temozolomide 6 obinutuzumab 5 daratumumab 5 Prednisone 5 Nivolumab 5 Doxorubicin 5 Cisplatin 5 Calcium Dobesilate 5 Bortezomib 5 zanubrutinib 4 selinexor 4 Immunotherapy, Adoptive 4 Cytarabine 4 Carboplatin 4 Azacitidine 4 ruxolitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Lomustine × 90 days × Clear all

NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡